This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Ramakrishnan TCR, Kumaravelu S, Narayan SK, et al. Efficacy and safety of intravenous tenecteplase bolus in acute ischemic stroke: results of two open-label, multicenter trials. Am J Cardiovasc Drugs. 2018;18(5):387–95.
Tang H, Foster NR, Grothey A, et al. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol. 2010;28:1936–41.
Arboix A, Alio J. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Curr Cardiol Rev. 2010;6:150–61.
Haley EC, Thompson JLP, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41:707–11.
Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099–107.
Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14:368–76.
Campbell BC, et al. Tenecteplase versus Alteplase before thrombectomy for ischaemic stroke. N Engl J Med. 2018;378:1573–82.
Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16:781–8.
Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49:e46–110.
Hill MD et al. A randomized controlled trial of TNK-tPA versus standard of care for minor ischemic stroke with proven occlusion (TEMPO-2). https://clinicaltrials.gov/ct2/show/NCT02398656. Accessed 27 Sep 2018.
Spratt N et al. Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363714&isReview=true. Accessed 27 Sep 2018.
Mathiesen EB et al. Tenecteplase in wake-up ischaemic stroke trial (TWIST). https://clinicaltrials.gov/ct2/show/NCT03181360. Accessed 27 Sep 2018.
Muir K et al. Alteplase–tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST-2). https://clinicaltrials.gov/ct2/show/NCT02814409. Accessed 27 Sep 2018.
Campbell B, Sallaberger M et al. Determining the optimal dose of tenecteplase before endovascular therapy for ischaemic stroke (EXTEND-IA TNK Part 2). https://clinicaltrials.gov/ct2/show/NCT03340493. Accessed 27 Sep 2018.
No sources of funding were used to assist with the preparation of this manuscript.
Conflicts of interest
Prashant Rana, Nilan Jacob, Tomson Toms, and Shraddha Bhure are employees of Boehringer Ingelheim India Pvt. Ltd., and have no additional conflicts of interest that might be relevant to the content of this letter.
About this article
Cite this article
Rana, P.B., Jacob, N.T., Toms, T. et al. Comment on: “Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials”. Am J Cardiovasc Drugs 19, 219–221 (2019). https://doi.org/10.1007/s40256-019-00333-9